The Library
Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
Tools
Mulders, Peter F., De Santis, Maria , Powles, Thomas and Fizazi, Karim (2015) Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunology, Immunotherapy, Volume 64 (Number 6). pp. 655-663. doi:10.1007/s00262-015-1707-3 ISSN 0340-7004.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1007/s00262-015-1707-3
Abstract
Context
Prostate cancer remains highly prevalent and has a poor clinical outcome once metastatic. Sipuleucel-T is an autologous cellular immunotherapy approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T treatment extends survival but is independent of traditional short-term markers of treatment response observed with chemotherapy and contemporary hormonal treatments. Therefore, it is essential that clinicians understand the mechanism of action of sipuleucel-T and how this can translate in the clinic.
Objective
This article aims to summarize the current knowledge of sipuleucel-T therapy and its effects in mCRPC.
Evidence acquisition
Relevant publications describing sipuleucel-T clinical data and information relating to immunotherapies were identified.
Evidence synthesis
Treatment with sipuleucel-T extends survival, with side effects being usually mild or moderate and manageable within the outpatient setting. The long-term immune responses generated by sipuleucel-T correlate with a survival benefit. Sipuleucel-T shows a greater magnitude of clinical benefit when used in patients earlier in the mCRPC setting.
Conclusions
Sipuleucel-T stimulates long-lived immune responses that translate into long-term clinical benefit. The treatment course (three infusions at weeks 0, 2, and 4) is associated with manageable side effects. Short-term markers of future benefit would be clinically useful, and information on effective treatment combinations or sequences is awaited.
Item Type: | Journal Article | ||||
---|---|---|---|---|---|
Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences > Cancer Research Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
Journal or Publication Title: | Cancer Immunology, Immunotherapy | ||||
Publisher: | Springer | ||||
ISSN: | 0340-7004 | ||||
Official Date: | 1 June 2015 | ||||
Dates: |
|
||||
Volume: | Volume 64 | ||||
Number: | Number 6 | ||||
Page Range: | pp. 655-663 | ||||
DOI: | 10.1007/s00262-015-1707-3 | ||||
Status: | Peer Reviewed | ||||
Publication Status: | Published | ||||
Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
View Item |